Product
Surufatinib+Toripalimab+AG
1 clinical trial
1 indication
Indication
Ampullary CarcinomaClinical trial
Efficacy and Safety of Surufatinib Combined With Toripalimab and AG Regiments for First-line Treatment of Unresectable or Relapsing Metastatic Ampullary CarcinomaStatus: Not yet recruiting, Estimated PCD: 2025-10-01